Biblio
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting. Exp Hematol Oncol. 2024;13(1):17.
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):57.